vanucizumab vanucizumab vanucizumab (inn; development code rg7221) is an experimental humanized monoclonal antibody designed for the treatment of cancer. vanucizumabmonoclonal antibodytypewhole antibodysourcehumanizedtargetangiopoietin 2clinical dataother namesrg7221atc codenoneidentifierscas number1448221-05-3chemspidernoneuniib800z06o8kkeggd11244chemical and physical dataformulac6529h10033n1733o2038s46molar mass146887.94 g·mol−1 vanucizumab is a bi-specific monoclonal antibody composed of two different heavy chains and two different light chains. one arm of the antibody binds angiopoietin-2 (ang2) and the other is based on bevacizumab (avastin), binding vascular endothelial growth factor a (vegf-a). the antibody is designed to inhibit both vegf-a and ang2 simultaneously to offer superior clinical benefit compared to vegf-a inhibition alone. this drug was developed by genentech/roche.